chronic kidney disease (stage 5)
Conditions
Interventions
two groups:calcium dobesilate vs placebo
Sponsors
the first affiliated hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years; 2. the duration of CAPD is more than 30 days; 3. good blood pressure (less than 140/90mmHg); 4. residual GFR of 2 mL/min per 1.73 m2 or more; 5. urine output is more than 400ml/d; 6. no history of taking calcium dobesilate for more three months; 7. signed informed consent.
Exclusion criteria
Exclusion criteria: 1. acute renal failure; 2. hemodialysis; 3. acute or chronic infection; peritonitis within 30 days; 4. severe diseases, such as cancer, infection, liver cirrhosis, congestive heart failure, anemia(Hb10mg/L; 5. pregnancy or lactation, refusal of using effective contraceptive measures during the test; 6. A history of alcoholism, drug abuse and HIV-positive; 7. Poor compliance or researchers think patients can not join the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hs-CRP, IL-6, IL-10, MCP-1;MDX, Trx;CD62P, soluble CD40 ligand;residal renal function; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood routine test, biochemical outcome; | — |
Countries
China
Contacts
Public ContactHongli Li
Outcome results
None listed